

2 3 MAY 2016

Freyberg Building
20 Aitken Street
PO Box 5013
Wellington 6145, New Zealand
T +64 4 496 2000
W www.medsafe.govt.nz

Ref: H201601585

Dear

Response to your request for official information

Thank you for your request of 21 April 2016 under the Official Information Act 1982 (the Act) for

"Assistance under the NZ FOIA, in obtaining the CARM statistical reports, pertaining to Gardasil vaccine adverse reports, specifically for the Christchurch, Canterbury Region. I would like the data that covers reports from the period of time of commencement of use of Gardasil in NZ, to present day, for this region.

I would be most obliged, if I could have a break down of those reported events which have been deemed related to Gardasil, by CARM and of these, how many were deemed serious. I would hope that the types of adverse events are also recorded. I am also wanting to know how many, if any claimants, have received ACC payments, as a result of Gardasil vaccine related injury".

The information relating to this request is itemised below, with a copy of the document attached.

Request	Response
CARM statistical reports, pertaining to Gardasil vaccine adverse reports, specifically for the Christchurch, Canterbury Region. I would like the data that covers reports from the period of time of commencement of use of Gardasil in NZ, to present day, for this region.	Attached is: 1. A report titled 'HPV Vaccine — Official Information Act Request' with a period of 01 September 2008 to 31 March 2016.
I would be most obliged, if I could have a break down of those reported events which have been deemed related to Gardasil, by CARM and of these, how many were deemed serious. I would hope that the types of adverse events are also recorded.	Attached is: 2. A report titled 'HPV Vaccine – Official Information Act Request' with a period of 01 September 2008 to 31 March 2016.

I am also wanting to know how many, if any claimants, have received ACC payments, as a result of Gardasil vaccine related injury.

This part of the request has been transferred to ACC.

I trust this information fulfils your request.

Yours sincerely

Acting Group Manager Medsafe



New Zealand Pharmacovigilance Centre

University of Otago PO Box 913, Dunedin, New Zealand Telephone: 64-3-479 7185 Fax: 64-3-479 7150

Email: nzphvc@otago.ac.nz Website: https://nzphvc.otago.ac.nz

Report Title:

HPV Vaccine Official Information Act Request

Prepared for:

Prepared by:

Centre for Adverse Reactions Monitoring (CARM

New Zealand Pharmacovigilance Centre

May 2016

Request:

dajted 21 April 2016) (NZPhvC interpretation)

Number of cases reported to CARWYor Gardasil vaccine

that meet the following criteria.

From Christeburch, Canterbury Region Period : 01 September 2008 to 31 March 2016

Assessed by CARM as 'related to Gardasil' (See Note 1)

Number of cases categorised serious (See Note 2)

Types of Adverse Events Following Immunisation (AEFIs) (See Note 3)

Number of ACC payments for Gardasil related injury

Summary

Data Lock Point:

31 March 2016

Total Reports from Christchurch, Canterbury

46

Total AEFIs from Christchurch, Canterbury

97

Serious cases

Number of ACC payments

Unknown to CARM



New Zealand Pharmacovigilance Centre

University of Otago PO Box 913, Dunedin, New Zealand Telephone: 64-3-479 7185 Fax: 64-3-479 7150

Email: nzphvc@otago.ac.nz Website: https://nzphvc.otago.ac.nz

Summary

Data Lock Point:

31 March 2016

Number of cases reported to CARM for Gardasil HPV vaccine that meet the following criteria

a. From Christchurch, Canterbury Region

b. Period: 01 September 2008 to 31 March 2016

c. Assessed by CARM as 'related to Gardasil' (Se

2015 (afos/

Note 1:

causality is assessed using a 6 level scale

Definitely Probably Possibly Unlikely

Awaiting further information to enable assessment Insufficient information to enable assessment

Related cases are those where the adverse events are assessed as

Definitely Probably

Possibly or linked to the vaccine

Number of cases categorised serious? (See Note 2)

Serious Cases 2

Note 2:

Definition of Seriousness

The following codes are used to define seriousness in accordance with international criteria as detailed in the ICH E2D guidelines:

- C = Congenital abnormality
- D = Died
- H = Hospitalisation or prolonged hospitalisation
- L = Life Threatening
- O = Intervention required to avoid permanent harm
- P = Persisting disability (at the time of the report)

Seriousness is assessed for each report based on the 'result/outcome of the adverse event(s)'; the individual events are not separately assessed for seriousness.



New Zealand Pharmacovigilance Centre University of Otago PO Box 913, Dunedin, New Zealand Telephone: 64-3-479 7185 Fax: 64-3-479 7150 Email: <u>nxphvc@otago.ac.nz</u> Website: https://nxphvc.otago.ac.nz

Types of Adverse Events (AEFIs) (See Note 3)

Table: HPV Vaccine - AEFIs per System Organ Class

Individual AEFIs by SOC ▼	Total
Alimentary	11/28
Injection Site	12
Cardiovascular	13
Haematological	
Musculoskeletal	12
Nervous System	22
Others	6
Psychiatric Changes	7
Respiratory	3
Skin-and Appendages	10
Special Senses	3
Total	97

The number of occurrences of each individual AEFI is in the appended listing

<u>AEFI</u> = Adverse Event Following Immunisation

		region		
		•	Christchurch	
		N	l N	į N
group	AEFI			
 Alimentary	NAUSEA	2	4	 6
	VOWITING	1	1	2
	*** Total for Group ***	3	5	8
Application Site	AEFI	† • • • • • • • • • • • • • • • • • • •		
	INJECTION SITE BRUISING	 1	2112	
	INJECTION SITE ERYTHEMA	i (
	INJECTION SITE INFLAMMATION	50	7	
	INJECTION SITE MASS			7
	INJECTION SITE PAIN		(())/().3	f
	INJECTION STE PRUNTING		1	t 1
	*** Fotal for Group ***	1 2	10	12
Cardiovascular	(AEP)	! !	·	! !
	BRADYCARDIA	 	 1] 1
	ICHEST PAIN	t 	1	•
	DIASINESS	t 	3	
2/2/2/2/	IFAINTNESS	+ 	1	1
	TACHYCARDIA	+	1	1
	VASOVAGAL REACTION] 3		6
	*** Total for Group ***] 3	10	13
Maematological	AEFI	†]		! !
	LYMPHOPENIA	I 	1	 1
	*** Total for Group ***	+ 	1	1
Musculoskeletal	AEFI	+		
	ARM PAIN	 1	3	 4
	 ARTHRALGIA	+ 	1;	t1 1
	BURSITIS	1		1
	 MYALGIA	2		
	PAIN NECK/SHOULDER	······································	·	2

(Continued)

		•	region		
		•	Christchurch	Total	
		N	и <u> </u>	N	
proup	*** Total for Group ***				
usculoskeletal			 6 6	12	
iervous System	AEFI		! !		
	DYSAESTHESIA		2	2	
	HEADACHE		41 81	12	
	NUMBNESS LOCALISED	1	21 / []	 کے ک	
	PAIN			\ (G	
	 PARAESTHESIA DISTAL	402	47.7.	1000	
	SHAKING			۱ ک	
	TWITCHING)\\	(\bigcirc)	1	
	*** Total for Group fry		16	22	
Others	AEFI		- + + - 		
	MANAPHYDACTIC REACTION	17	1	1	
	FEELING OF WARMTH		-+	1	
	FEVER	1	3	3	
20/10/	PALLOR TITE		1	1	
2/2/2	Total for Group ***		- +	6	
sychietric Changes	AEFI	!	-+		
	 FATIGUE			1	
	LETHARGY		-++- 1	1	
	NERVOUSNESS		-++- 1	1	
	SOMNOLENCE	 	-++- 1[1	2	
	 TIREONESS		-++- 1 1	2	
	*** Total for Group ***		-++- 3[4	7	
Respiratory	AEFI		-+		
	 BRONCHOSPASM		1 1	1	
	COUGHING	1	1 1	1	
	THROAT SORE	I	-++- 1	1	
	*** Total for Group ***		-++- 1] 2]	3	

(Continued)

			region	
			Canterbury Christchurch	
		N	N I	N
group	AEFI			
Skin and Appendages	MORBILLIFORM RASH]	1 1	1
	PRURITUS	1	1]	1
	RASH	•	3	5
	RASH PRURITIC	1		2
	URTICARIA			<i>></i> ~\`
	*** Total for Group ***		7	((10
Special Senses	AEFI	200	7	
	EYE PAIN) N 1
	MYDRIASIS			1
	РНОТОРНОВІА		1	1/
	Total for Group ***		2]	3
Total AEFIs		7 7	69	97

PIELE ASTE